Sarepta Therapeutics Inc SRPT, a developer of innovative RNA-targeted therapeutics, revealed Wednesday that the U.S. Food and Drug Administration has notified that they were continuing their review in respect of Eteplirsen.
The company indicated that the regulator was holding internal discussions related to its pending NDA for eteplirsen. Sarepta indicated that the FDA would not be in a position to complete their work by the Prescription Drug User Fee Act (PDUFA) goal date of May 26, 2016.
Related Link: Strange Price Action In Sarepta Therapeutics
Sarepta said that as a result, the FDA communicated that they would continue to work past the PDUFA goal date and strive to complete their work in as timely a manner as possible.
Following the news, the stock surged 23.6 percent in the pre-market trading on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
